Under the agreement, we are responsible for the development, manufacturing and supply of the collaboration biosimilar. Sandoz have global commercialisation rights.Learn more
The biosimilar was originally licensed from Formycon AG and subsequently developed by Bioeq AGLearn more
Coherus BioSciences, Inc. have commercialisation rights to the biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®) in the United States.Learn more
Teva Pharmaceutical Industries Ltd have commercialisation rights to the biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®) in Europe, Canada, Israel and New Zealand.Learn more
Our areas of interest
We focus on developing biosimilars that will be first to market or where there is a significant market potential. These can be either for blockbuster originators or niche disease areas. As a company we consistently invest in the start of new biosimilar developments every year based upon expert market analysis, clinical evaluation, and an extensive manufacturing assessment.
Our approach to partnering
Currently, there is no company on the Polish market with scale comparable to ours and with a similar business model. We are able to handle biosimilars from the concept stage to large scale production. We are currently progressing up to 10 biosimilars, of which 2 are closing on market approval. These leading biosimilars are partnered with multiple companies for marketing rights to different territories.
We are always looking to partner with companies that share our ethos of expanding market access of much needed therapeutics, we are especially interested in discussing partnerships with companies who are looking to take on marketing rights for major territories including the US, Europe and Asia.
For more information please get in touch.
Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (“Bioeq”), jointly announ...
Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) has accepted the first-ever Biol...
European Medicines Agency (EMA) has accepted the first-ever Marketing Authorization Application (MAA) for biosimilar...
We are pleased to share last week’s news on the approval of the marketing authorization application of BIOEQ’s Lucent...